Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sinovac Receives 20 Million Yuan For Hep A Vaccine From China’s MOH For Quake Victims

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Sinovac has received a 20 million yuan ($ 2.86 million) order from the Ministry of Health for its hepatitis A vaccine Healive, for the quake-affected area of Sichuan, the company announced May 27

You may also be interested in...



Sinovac To Launch New Vaccines In China; Chinese Government Biggest Purchaser

SHANGHAI - Sinovac saw increased income and profits from vaccine sales, including a first order for hepatitis vaccines placed by the Chinese government during the Sichuan earthquake in the first half of the year, according to financial results for the period ended June 30

Sinovac To Launch New Vaccines In China; Chinese Government Biggest Purchaser

SHANGHAI - Sinovac saw increased income and profits from vaccine sales, including a first order for hepatitis vaccines placed by the Chinese government during the Sichuan earthquake in the first half of the year, according to financial results for the period ended June 30

Sinovac CEO Weidong Yin On China’s Evolving Vaccine Market: An Interview With PharmAsia News

Sinovac Biotech CEO Weidong Yin recently spoke with PharmAsia News' Shanghai bureau about the Chinese vaccine market and the impact of current government policies on vaccine makers. Sinovac was established in April 2001 as a result of a joint venture between Sino Pharma, Shenzhen Kexing and Tangshan Yian. The Beijing-based company manufactured its first hepatitis A vaccine and sold its first dose in 2002. In December 2004, it was listed on the American Stock Exchange.

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel